Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2026-01-01 @ 9:51 PM
Study NCT ID:
NCT05098132
Status:
RECRUITING
Last Update Posted:
2025-11-28
First Post:
2021-10-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582435', 'term': 'pembrolizumab'}, {'id': 'D000068437', 'term': 'Pemetrexed'}, {'id': 'D016190', 'term': 'Carboplatin'}], 'ancestors': [{'id': 'D006147', 'term': 'Guanine'}, {'id': 'D007042', 'term': 'Hypoxanthines'}, {'id': 'D011688', 'term': 'Purinones'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005971', 'term': 'Glutamates'}, {'id': 'D024342', 'term': 'Amino Acids, Acidic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D000600', 'term': 'Amino Acids, Dicarboxylic'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 364}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-01-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2029-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-21', 'studyFirstSubmitDate': '2021-10-06', 'studyFirstSubmitQcDate': '2021-10-20', 'lastUpdatePostDateStruct': {'date': '2025-11-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2021-10-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase 1a: Treatment emergent adverse events (TEAEs)', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of TEAEs in participants with select advanced solid tumors'}, {'measure': 'Phase 1a: Serious adverse events (SAEs)', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of SAEs in participants with select advanced solid tumors'}, {'measure': 'Phase 1a: Dose limiting toxicities (DLTs)', 'timeFrame': 'Cycle 1, Days 1 through 21', 'description': 'Incidence of DLTs in participants with select advanced solid tumors'}, {'measure': 'Phase 1a: Deaths', 'timeFrame': 'From 1st dose of study treatment until death, up to 4 years', 'description': 'Incidence of death in participants with select advanced solid tumors'}, {'measure': 'Phase 1b: TEAEs at the RP2D', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of TEAEs at the recommended phase 2 dose (RP2D) in participants with select advanced solid tumors'}, {'measure': 'Phase 1b: SAEs at the RP2D', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of SAEs at the RP2D in participants with select advanced solid tumors'}, {'measure': 'Phase 1b: Deaths at the RP2D', 'timeFrame': 'From 1st dose of study treatment until death, up to 4 years', 'description': 'Incidence of death at the RP2D in participants with select advanced solid tumors'}, {'measure': 'Phase 2: Overall response rate (ORR) in Arm A versus Arm C', 'timeFrame': 'From randomization until disease progression or death, or the last evaluable assessment in the absence of progression, up to 4 years', 'description': 'To compare the ORR in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 2.25 mg + SoC vs. SoC (Arms A vs. C). ORR is the proportion of subjects with confirmed complete response (CR) or confirmed partial response (PR) per BICR.'}], 'secondaryOutcomes': [{'measure': 'Phase 1: ORR', 'timeFrame': 'From enrollment until disease progression or death, or the last evaluable assessment in the absence of progression, up to 4 years', 'description': 'Assessment of preliminary efficacy, specifically ORR, in select advanced solid tumors. ORR is the proportion of subjects with confirmed CR or confirmed PR per investigator assessment.'}, {'measure': 'Phase 1: Progression free survival (PFS)', 'timeFrame': 'From enrollment until first documentation of disease progression per investigator assessment or death due to any cause, whichever occurs first, up to 4 years', 'description': 'Assessment of preliminary efficacy, specifically PFS, in select advanced solid tumors.'}, {'measure': 'Phase 1: Overall survival (OS)', 'timeFrame': 'From enrollment until death due to any cause, up to 4 years', 'description': 'Assessment of preliminary efficacy, specifically OS, in select advanced solid tumors.'}, {'measure': 'Phase 1/2: STK-012 ADAs', 'timeFrame': 'From screening through 30 days after last dose of STK-012', 'description': 'Anti-drug antibodies (ADA) to assess immunogenicity of STK-012 in advanced NSCLC and other select solid tumors.'}, {'measure': 'Phase 1/2: AUC of STK-012', 'timeFrame': 'From screening through 30 days after last dose of STK-012', 'description': 'Area under the curve (AUC) to assess pharmacokinetic (PK) characterization of STK-012 in advanced NSCLC and other select solid tumors.'}, {'measure': 'Phase 1/2: Cmax of STK-012', 'timeFrame': 'From screening through 30 days after last dose of STK-012', 'description': 'Maximum concentration (Cmax) to assess PK characterization of STK-012 in advanced NSCLC and other select solid tumors.'}, {'measure': 'Phase 1/2: Tmax of STK-012', 'timeFrame': 'From screening through 30 days after last dose of STK-012', 'description': 'Time of maximum concentration (Tmax) to assess PK characterization of STK-012 in advanced NSCLC and other select solid tumors.'}, {'measure': 'Phase 1/2: Half life of STK-012', 'timeFrame': 'From screening through 30 days after last dose of STK-012', 'description': 'Half life (t1/2) to assess PK characterization of STK-012 in advanced NSCLC and other select solid tumors.'}, {'measure': 'Phase 2: PFS in Arm A versus Arm C', 'timeFrame': 'From randomization until first documentation of disease progression per BICR or death due to any cause, whichever occurs first, up to 4 years', 'description': 'To compare the PFS in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 2.25 mg + SoC vs. SoC (Arms A vs. C). PFS is the time from randomization until the first documentation of disease progression per BICR or death due to any cause, whichever occurs first.'}, {'measure': 'Phase 2: ORR in Arm B versus Arm C', 'timeFrame': 'From randomization until disease progression or death, or the last evaluable assessment in the absence of progression, up to 4 years', 'description': 'To compare the ORR in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 1.5 mg + SoC vs. SoC (Arms B vs. C). ORR is the proportion of subjects with confirmed CR or confirmed PR per BICR.'}, {'measure': 'Phase 2: PFS in Arm B versus Arm C', 'timeFrame': 'From randomization until first documentation of disease progression per BICR or death due to any cause, whichever occurs first, up to 4 years', 'description': 'To compare the PFS in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 1.5 mg + SoC vs. SoC (Arms B vs. C). PFS is the time from randomization until the first documentation of disease progression per BICR or death due to any cause, whichever occurs first.'}, {'measure': 'Phase 2: OS in Arm A versus C', 'timeFrame': 'From randomization until death due to any cause, up to 4 years', 'description': 'To compare the OS in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 2.25 mg + SoC vs. SoC (Arms A vs. C). OS is the time from randomization until death due to any cause.'}, {'measure': 'Phase 2: OS in Arm B versus C', 'timeFrame': 'From randomization until death due to any cause, up to 4 years', 'description': 'To compare the OS in 1L PD-L1 negative NSQ NSCLC subjects treated with STK-012 1.5 mg + SoC vs. SoC (Arms B vs. C). OS is the time from randomization until death due to any cause.'}, {'measure': 'Phase 2: TEAEs', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of TEAEs in 1L PD-L1 negative NSQ NSCLC'}, {'measure': 'Phase 2: SAEs', 'timeFrame': 'From 1st dose of study treatment through 90 days after last dose', 'description': 'Incidence of SAEs in 1L PD-L1 negative NSQ NSCLC'}, {'measure': 'Phase 2: Deaths', 'timeFrame': 'From 1st dose of study treatment until death, up to 4 years', 'description': 'Incidence of death in 1L PD-L1 negative NSQ NSCLC'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Advanced Solid Tumor', 'Non Small Cell Lung Cancer', 'Untreated Advanced NSCLC', '1st Line NSCLC']}, 'descriptionModule': {'briefSummary': 'This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative, non-squamous, non-small cell lung cancer.', 'detailedDescription': 'Phase 1 \\[closed to enrollment\\]: The phase 1a portion is a dose escalation study to evaluate STK-012 as monotherapy and in combination therapy in patients with selected solid tumors. The phase 1b portion is a dose expansion study to evaluate STK-012 as monotherapy and in combination therapy at the candidate recommended phase 2 dose (RP2D) in selected solid tumor types.\n\nPhase 2 \\[open to enrollment\\]: The phase 2 portion is a randomized, open label study to evaluate STK-012 at two dose levels in combination with standard of care (SoC) pembrolizumab, pemetrexed and carboplatin, versus SoC, in patients with first line, PD-L1 negative, non-squamous, non-small cell lung cancer.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Selected Inclusion Criteria:\n\n1. Phase 1 \\[closed to enrollment\\]\n2. Phase 2 \\[open to enrollment\\]:\n\n * Diagnosis of non-small cell lung cancer (NSCLC).\n * Stage IV or Stage IIIB/IIIC and not a candidate for definitive treatment.\n * Non-squamous (NSQ) cell histology.\n * No prior systemic therapy for advanced/metastatic NSQ NSCLC.\n * Tumor is PD-L1 negative (TPS \\<1%) by local testing.\n * No known actionable EGFR, ALK, ROS1, or other actionable genomic aberrations for which there is a local standard of care available as front line therapy.\n\nSelected Exclusion Criteria:\n\n1. Phase 1 \\[closed to enrollment\\]\n2. Phase 2 \\[open to enrollment\\]:\n\n * Prior immune checkpoint inhibitor (anti-PD\\[L\\]1 and/or anti-CTLA-4) treatment\n * Tumor with small cell, neuroendocrine, or sarcomatoid components.\n * Received radiotherapy ≤ 7 days of the first dose of study treatment.\n * Known untreated central nervous system metastases\n * Any history of carcinomatous meningitis'}, 'identificationModule': {'nctId': 'NCT05098132', 'acronym': 'SYNERGY-101', 'briefTitle': 'Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Synthekine'}, 'officialTitle': 'A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications', 'orgStudyIdInfo': {'id': 'STK-012-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Phase 1a: STK-012 monotherapy dose escalation', 'description': 'STK-012 subcutaneous (SC) as monotherapy in selected solid tumor indications', 'interventionNames': ['Drug: STK-012']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1a: STK-012 + pembrolizumab dose escalation', 'description': 'STK-012 SC + pembrolizumab intravenously (IV) in selected solid tumor indications', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'description': 'STK-012 SC + SoC IV in first-line non-squamous (NSQ) NSCLC', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab', 'Drug: pemetrexed', 'Drug: carboplatin']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1b: STK-012 monotherapy expansion', 'description': 'STK-012 SC monotherapy in selected solid tumor indications', 'interventionNames': ['Drug: STK-012']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1b: STK-012 + pembrolizumab dose expansion', 'description': 'STK-012 SC will be administered in combination with pembrolizumab IV in selected solid tumor indications', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1b: STK-012 + SoC dose expansion', 'description': 'STK-012 SC + SoC IV in first-line PD-L1 negative NSQ NSCLC', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab', 'Drug: pemetrexed', 'Drug: carboplatin']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2: Arm A', 'description': 'STK-012 2.25 mg SC Q3W + SoC IV in first-line PD-L1 negative NSQ NSCLC', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab', 'Drug: pemetrexed', 'Drug: carboplatin']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2: Arm B', 'description': 'STK-012 1.5 mg SC Q3W + SoC IV in first-line PD-L1 negative NSQ NSCLC', 'interventionNames': ['Drug: STK-012', 'Drug: pembrolizumab', 'Drug: pemetrexed', 'Drug: carboplatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Phase 2: Arm C', 'description': 'SoC IV in first-line PD-L1 negative NSQ NSCLC', 'interventionNames': ['Drug: pembrolizumab', 'Drug: pemetrexed', 'Drug: carboplatin']}], 'interventions': [{'name': 'STK-012', 'type': 'DRUG', 'description': 'Engineered Interleukin-2 (IL-2) selective for antigen activated T cells', 'armGroupLabels': ['Phase 1a: STK-012 + pembrolizumab dose escalation', 'Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1a: STK-012 monotherapy dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 1b: STK-012 + pembrolizumab dose expansion', 'Phase 1b: STK-012 monotherapy expansion', 'Phase 2: Arm A', 'Phase 2: Arm B']}, {'name': 'pembrolizumab', 'type': 'DRUG', 'description': 'anti-PD-1 monoclonal antibody', 'armGroupLabels': ['Phase 1a: STK-012 + pembrolizumab dose escalation', 'Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 1b: STK-012 + pembrolizumab dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C']}, {'name': 'pemetrexed', 'type': 'DRUG', 'description': 'chemotherapy', 'armGroupLabels': ['Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C']}, {'name': 'carboplatin', 'type': 'DRUG', 'description': 'chemotherapy', 'armGroupLabels': ['Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85721', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mikayla Kirby', 'role': 'CONTACT', 'email': 'mikaylakirby@arizona.edu'}], 'facility': 'University of Arizona Cancer Center', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '90211', 'city': 'Beverly Hills', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ali Muhammad', 'role': 'CONTACT', 'email': 'amuhammad@bhcancercenter.com'}], 'facility': 'Beverly Hills Cancer Center', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}}, {'zip': '92835', 'city': 'Fullerton', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Linda Gozar', 'role': 'CONTACT', 'email': 'linda.gozar@stjoe.org'}], 'facility': 'Providence Medical Foundation', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'zip': '92093-0698', 'city': 'La Jolla', 'state': 'California', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'UC San Diego Moores Cancer Center', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ariel Klingfus', 'role': 'CONTACT', 'email': 'ariel.klingfus@hoag.org', 'phone': '949-764-6755'}, {'name': 'Holland Orndorff', 'role': 'CONTACT', 'email': 'holland.orndorff@hoag.org', 'phone': '949-764-7110'}], 'facility': 'Hoag Memorial Hospital Presbyterian', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '90404', 'city': 'Santa Monica', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jacky Banuelos', 'role': 'CONTACT', 'email': 'JBanuelosMurillo@mednet.ucla.edu', 'phone': '310-633-8400'}], 'facility': 'UCLA Hematology/Oncology - Santa Monica', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jialing Zhang, PhD', 'role': 'CONTACT', 'email': 'jialing.zhang@yale.edu', 'phone': '475-234-9684'}], 'facility': 'Yale New Haven Hospital, Yale Cancer Center', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '20057', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Stephen Liu, MD', 'role': 'CONTACT', 'email': 'Stephen.Liu@gunet.georgetown.edu', 'phone': '202-444-2223'}], 'facility': 'Georgetown University', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Issie Hart', 'role': 'CONTACT', 'email': 'isioma.hart@emory.edu', 'phone': '404-778-4576'}], 'facility': 'Winship Cancer Institute, Emory University', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Justin Gainor, MD', 'role': 'CONTACT', 'email': 'jgainor@mgh.harvard.edu', 'phone': '617-724-4000'}], 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Alexandra Childs, NP', 'role': 'CONTACT', 'email': 'achilds1@bidmc.harvard.edu'}], 'facility': 'Beth Israel Deaconess Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Julia Rotow, MD', 'role': 'CONTACT', 'email': 'Julia_Rotow@dfci.harvard.edu', 'phone': '877-442-3324'}], 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55101', 'city': 'Saint Paul', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lisa Wahowske', 'role': 'CONTACT', 'email': 'Lisa.Wahowske@ParkNicollet.com', 'phone': '651-254-1517'}], 'facility': 'HealthPartners Cancer Center at Regions Hospital', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '11042', 'city': 'Lake Success', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Northwell Cancer Trials', 'role': 'CONTACT', 'email': 'NorthwellCancerTrials@northwell.edu', 'phone': '(516) 734-8896'}], 'facility': 'Northwell Health', 'geoPoint': {'lat': 40.77066, 'lon': -73.71763}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Salman Punekar, MD', 'role': 'CONTACT', 'email': 'salman.punekar@nyulangone.org'}, {'name': 'Joshua Sabari, MD', 'role': 'CONTACT', 'email': 'joshua.sabari@nyulangone.org'}], 'facility': 'NYU Langone Health', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'Columbia University Irving Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Adam Schoenfeld, MD', 'role': 'CONTACT', 'email': 'schoenfa@mskcc.org'}], 'facility': 'Memorial Sloan-Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'email': 'CCI-TrialReferrals@duke.edu', 'phone': '(919) 681-6468'}], 'facility': 'Duke Cancer Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Danny Lawson', 'role': 'CONTACT', 'email': 'danny.lawson@osumc.edu', 'phone': '614-257-2796'}, {'name': 'Kai He, MD', 'role': 'CONTACT', 'email': 'kai.he@osumc.edu', 'phone': '614-293-2366'}], 'facility': 'The James Cancer Hospital and Solove Research Institute', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'UPMC Hillman Cancer Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '38120', 'city': 'Memphis', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Julie Ryder', 'role': 'CONTACT', 'email': 'julie.ryder@bmhcc.org', 'phone': '(901) 226-1577'}], 'facility': 'Baptist Memorial Hospital Cancer Center', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'Sarah Cannon Research Institute - Nashville', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '79915', 'city': 'El Paso', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mary Crow, MD', 'role': 'CONTACT', 'email': 'mary.crow@renovatioclinical.com', 'phone': '713-703-2398'}, {'name': 'Jennifer Bustamante', 'role': 'CONTACT', 'email': 'jennifer.bustamante@renovatioclinical.com', 'phone': '713-703-2398'}], 'facility': 'Renovatio Clinical', 'geoPoint': {'lat': 31.75872, 'lon': -106.48693}}, {'zip': '77303', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Julio Peguero, MD', 'role': 'CONTACT', 'email': 'jpeguero@OncologyConsultants.com'}, {'name': 'Laura Guerra', 'role': 'CONTACT', 'email': 'lguerra@oncologyconsultants.com', 'phone': '713-600-0900'}], 'facility': 'Oncology Consultants', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77380', 'city': 'The Woodlands', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mary Crow, MD', 'role': 'CONTACT', 'email': 'mary.crow@renovatioclinical.com', 'phone': '713-703-2398'}, {'name': 'Jennifer Bustamante', 'role': 'CONTACT', 'email': 'jennifer.bustamante@renovatioclinical.com', 'phone': '713-703-2398'}], 'facility': 'Renovatio Clinical', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Blake Patterson', 'role': 'CONTACT', 'email': 'bpatterson@nextoncology.com', 'phone': '703-783-4505'}], 'facility': 'NEXT Virginia', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'CarrieAnn Brown', 'role': 'CONTACT', 'email': 'cbrown@nwmsonline.com', 'phone': '253-428-8700'}, {'name': 'Kiersten Peart', 'role': 'CONTACT', 'email': 'kpeart@nwmsonline.com', 'phone': '253-428-8700'}], 'facility': 'Northwest Medical Specialties', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}], 'centralContacts': [{'name': 'Synthekine STK-012-101 Contact', 'role': 'CONTACT', 'email': 'STK-012-101.contact@synthekine.com', 'phone': '650-606-6319'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Synthekine', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}